NIH unit awards vaccine contract to Crucell

10/5/2008 | Boston Globe (tiered subscription model), The

Crucell announced that it secured a contract worth as much as $70 million from the National Institute of Allergy and Infectious Diseases to develop vaccines for the Ebola and Marburg viruses, which are responsible for hemorrhagic fever. The Dutch biotech firm said it will work with the Southwest Foundation for Biomedical Research in San Antonio and Quintiles Guy's Drug Research Unit in London for the project.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL